Known hereditary thrombophilia and vWF promoter polymorphism haplotype 1 are used as criteria to decide the starting of thromboprophylaxis in patients with CS by 30% and 13% of centers, respectively. This evidence concerns the gene VWF and Cowden syndrome 1.